医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion®

2021年01月29日 AM05:19
このエントリーをはてなブックマークに追加


 

TAMPA, Fla.

Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128006046/en/

(Photo: Business Wire)

(Photo: Business Wire)

Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled stimulation to the occipital and trigeminal nerves. This creates a cumulative effect by releasing neurotransmitters in the brainstem and modulating brain networks associated with control of pain and mood. The device is designed to allow patients to use Relivion® at home, and share treatment data with their physician, in addition to uploading the data to the cloud database through a dedicated app. It is also designed to self-learn and analyze the treatments using AI technology in order to optimize the treatments for patients according to their symptoms.

*Neuromodulation: A therapeutic technology to modulate neurological activities through the administration of electric/magnetic stimuli or drugs.

With the view to launch Relivion in Japan, submissions to the Pharmaceuticals and Medical Devices Agency (PMDA) are expected for migraine by 2022 and depression by 2023. If Relivion® is approved by the agency, it will be the only brain neuromodulation device available for treatment at home in Japan.

*In Europe, Neurolief obtained the CE Mark certification as a treatment device for migraine and is in preparation for the market launch. In the US, the application was filed to FDA in November 2020 as a 510(K) submission for migraine and is scheduled to be filed for depression by 2022.

By working with Sawai to introduce the Relivion® neuromodulation device in Japan for use at home with doctor’s supervision, we are widening treatment options for patients who are suffering from either migraine or depression.

About Neurolief

Dedicated to bringing relief to patients suffering from chronic neurological and neuropsychiatric disorders, Neurolief is creating a digital therapeutics platform of wearable clinically-proven neuromodulation solutions. This technology, which is made to be worn like a headset, is intended to offer highly effective, safe treatment options that work with current pharmaceutical therapies or may provide an alternative to these therapies. It is designed to concurrently neuromodulate major neural pathways in the head, and thereby affect brain regions that are involved in control and modulation of mood and pain. Neurolief’s technology is currently studied for patients with migraine and major depression, and future indications may include insomnia, ADHD and additional chronic pain and neuropsychiatric disorders. The company is based in Israel, with US operations in Tampa, FL and is made up of highly experienced professionals with a proven track record in neurosciences, neuromodulation technology and the neurotech devices industry. For more information, visit https://www.neurolief.com/

*The Trademark application for Relivion in Japan has been filed by Neurolief.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210128006046/en/

CONTACT

Neurolief, Ltd.

Chris Richardson

chris.richardson@neurolief.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • すい臓疾患検出用の革新的なAIソフトウエアのヒト初回適用が成功
  • “Everyday Japan Expo” Melo Became Brand New Sterilized Retail Shop in Singapore.
  • 【日本企業唯一】3歳未満向けの乳幼児用食品に使用が認められたプロバイオティクス※1 『ビフィズス菌BB536』が中国「新食品原料」に登録※2
  • City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
  • 内布拉斯加大学医学中心和阿南达宣布,FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验